Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3

Interventions

pembrolizumab 185Carboplatin 131Paclitaxel 123Gemcitabine 122Docetaxel 97Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 65Bevacizumab 65Capecitabine 60atezolizumab 55fludarabine 49Fluorouracil 49Azacitidine 49130-nm albumin-bound paclitaxel 43Irinotecan 42venetoclax 41Trastuzumab 41Cetuximab 40Leucovorin 37Ipilimumab 36Erlotinib Hydrochloride 35Oxaliplatin 32Fulvestrant 32Cytarabine 32avelumab 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × TLC 388 × Clear all
NCT02267213 2019-02-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 2 Terminated
29 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03035006 2018-11-06

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Taiwan Liposome Company

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01425996 2018-08-21

A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔